Commentaries

17 October 2017

ERS 2017 Asthma Back in Focus

ERS 2017At the European Respiratory Society (ERS) Congress September 9 – 12, Milan, there was a renewed interest in asthma, with several new approaches to the treatment of severe asthma being presented. This interest was sparked by new data and events in the asthma space.


Click thumbnail to download

14 June 2016

TranScrip's Tim Joslin reflects on the recent American Thoracic Society 2016 (ATS) conference

ATS 2016 Overview Commentary_14Jun2015.jpgThe American Thoracic Society 2016 (ATS)  in San Francisco was better attended than previous years (over 17,000 registered delegates from 90 countries, with nearly 7,000 scientific abstracts, case reports, and late-breaking abstracts were presented).  It saw the resurgence/return of the major players in Respiratory (GSK, AZ, Sanofi) due to on-going interest in idiopathic pulmonary fibrosis (IPF), the advent of biological therapies for asthma (anti IL-4, anti-IL-5, anti-IL-13) plus the surge in phenotyping and endotyping for asthma and chronic obstructive pulmonary disease (COPD).


Click thumbnail to download

10 March 2016

Idiopathic Pulmonary Fibrosis – Implications of 2015 guideline updates

Idiopathic Pulmonary Fibrosis Implication of 2015 guideline updates_Final 10 Mar 2016_FRONT PAGE.jpgJust over a decade ago research into Idiopathic Pulmonary Fibrosis (IPF) and dedicated drug development was very limited. However recent improvements in the understanding of the underlying biology, and the success of developmental agents to show a measurable positive effect on lung function, have spurred pharmaceutical companies to take a serious interest in the disease.


Click thumbnail to download

27 November 2015

TranScrip’s Lars Larsson reports back from the European Respiratory Society Congress (ERS 2015)

Post ERS Congress Report 27Nov2015.png27th November 2015: The yearly congress of European Respiratory Society was held in Amsterdam from September 26 – 30, 2015. The event further established ERS as the largest respiratory congress in the world with about 20,000 delegates and more than 400 scientific sessions.


Click thumbnail to download

19 June 2015

Cystic Fibrosis – future market opportunity? By Senior Partner, Tim Joslin

Cystic Fibrosis Market Opportunity commentary pic.jpgCystic fibrosis (CF) is an autosomal recessive disorder affecting about 80,000 Caucasians worldwide. It is a multisystem disease primarily affecting the lungs, causing thick viscous secretions and recurrent respiratory infections that both lead to continuous reductions in lung function.….

click on the thumbnail to download the complete commentary

17 June 2015

TranScrip’s Tim Joslin and Lars Larsson report back from the American Thoracic Society Conference (ATS 2015)

ATS 2015 Front page.png12th June 2015: This year’s congress of the American Thoracic Society (ATS) was attended by about 14,000 delegates, and 5,500 research abstracts were presented. The meeting was dominated by discussions on idiopathic pulmonary fibrosis (IPF), as with London buses you wait for ages then they come all at once (two new productspirfenidone and nintedanib approved in late 2014 in the US, pirfenidone previously approved in the EU)!

click on the thumbnail to download the complete commentary

11 June 2014

TranScrip Partners report on ATS 2014 highlights, by Senior Partners Paul Branthwaite and Lars Larsson

AJDDP-2-110-Tillotson-G-Antibiotic-development-in-an-era-of-antibiotic-drug-development-acute-skin-infections.png11th June 2014: The yearly congress of American Thoracic Society (ATS) was held in San Diego May 16 – 21. Over the five days more than 500 sessions, 800 speakers, and 5,700 original research abstracts and case reports in adult and paediatric pulmonary, critical care, and sleep medicine were presented and discussed by 14000 delegates.

click on the thumbnail to download the complete commentary

16 May 2013

Electronic Recording of Exacerbations in COPD. Is it as good as paper?

Electronic-recordings-of-exacerbations-in-COPD.pngDoes electronic recording for evaluating exacerbations in COPD really work better than paper? Drug developers working on COPD have all asked the question: ”Can we get better data from electronic recording than from paper diary cards?” Two recent studies have been designed to determine whether a conventional paper based diary system or an electronic handheld device is better able to collect COPD exacerbations (patient reported outcome (PRO) data) which are vital for evaluating new treatments for COPD.

click on the thumbnail to download the complete commentary